Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2019, Blueprint Medicines Corporation announced its financial results forthe quarter and year ended December 31, 2018 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit relating to Item 2.02 of this Current Report on Form 8-Kshall be deemed to be furnishedand not filed:
Blueprint Medicines Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 bpmc_Ex99_1 Exhibit 99.1 Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results — Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter — — BLU-667 receives Breakthrough Therapy Designation for the treatment of RET mutation-positive medullary thyroid cancer — — Continued clinical progress across the portfolio with dosing initiated in registration-enabling Phase 2 PIONEER trial of avapritinib in indolent systemic mastocytosis and Phase 1 trial of BLU-782 in healthy volunteers — — Avapritinib and BLU-667 data submitted for presentation at ASCO — CAMBRIDGE,…
To view the full exhibit click here
About Blueprint Medicines Corporation (NASDAQ:BPMC)
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).
